Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67

1991 ◽  
Vol 18 (3) ◽  
pp. 149-154 ◽  
Author(s):  
W. Weikel ◽  
T. Beck ◽  
M. Mitze ◽  
P. G. Knapstein
Keyword(s):  
Monoclonal Antibody ◽  
Breast Cancers ◽  
Human Breast ◽  
Ki 67

scholarly journals Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.

1986 ◽  
Vol 39 (9) ◽  
pp. 977-980 ◽  
Author(s):  
J Gerdes ◽  
R J Lelle ◽  
H Pickartz ◽  
W Heidenreich ◽  
R Schwarting ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Breast Cancers ◽  
Ki 67

How to reduce Ki67 variability jointly evaluating histological grade.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 127-127
Author(s):  
Maxim Izquierdo ◽  
Ignacio Rodriguez ◽  
Fransec Tresserra ◽  
Rafael Fabregas
Keyword(s):  
Monoclonal Antibody ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Histological Grade ◽  
High Variability ◽  
Clinical Use ◽  
Breast Cancers ◽  
Ki 67 ◽  
Hormonal Receptor Status ◽  
Grade Iii

127 Background: Proliferative tumor activity measured immunohistochemically by Ki67 has high variability. Clinical use can be improved if it is considered together with the histological grade. Methods: Ki67 value has been studied in 566 breast cancers between 2007 and 2013 at our Institution using MIBI monoclonal antibody. The histological grade and hormonal receptor status were also evaluated. Results: Histological grade was I in 293 (51.7%) tumors, II in 219 (38.7%) and III in 54 (16.8%) tumors. Estrogen receptor was positive in 166 (29.5%) tumors and progesterone receptor was positive in 95 (16.8%) tumors. None of the tumors with Ki 67 value lower than 10% had histological grade III. Only 7% of tumors with histological grade I had a Ki 67 higher than 25%. Conclusions: It has to be considered to repeat or confirm the values of Ki67 higher than 25% with histological grade I, and Ki67 values lower than 10% in tumors with histological grade III.

Bispecific monoclonal antibody therapy (anti HER-2/neu × anti CD 64) for human breast cancers that overexpress HER-2/neu

1993 ◽  
Vol 53 (S17G) ◽  
pp. 255-256
Author(s):  
Frank H. Valone ◽  
Peter A. Kaufman ◽  
Michael W. Fanger ◽  
Paul M. Guyre ◽  
Clark Springgate
Keyword(s):  
Monoclonal Antibody ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy ◽  
Breast Cancers ◽  
Human Breast ◽  
Bispecific Monoclonal Antibody ◽  
Her 2

Cell cycle-dependent reactivity with the monoclonal antibody Ki-67 during myeloid cell differentiation

1988 ◽  
Vol 179 (1) ◽  
pp. 79-88 ◽  
Author(s):  
Robert P. Wersto ◽  
Fritz Herz ◽  
Robert E. Gallagher ◽  
Leopold G. Koss
Keyword(s):  
Cell Cycle ◽  
Monoclonal Antibody ◽  
Cell Differentiation ◽  
Myeloid Cell ◽  
Ki 67 ◽  
Cycle Dependent

scholarly journals MRCKα Is Dispensable for Breast Cancer Development in the MMTV-PyMT Model

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 942
Author(s):  
Mei Qi Kwa ◽  
Rafael Brandao ◽  
Trong H. Phung ◽  
Jianfeng Ge ◽  
Giuseppe Scieri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression Signature ◽  
Genomic Analysis ◽  
Cancer Development ◽  
Breast Cancer Cell Lines ◽  
Normal Mammary Gland ◽  
Breast Cancers ◽  
Human Breast ◽  
Breast Cancer Development

MRCKα is a ubiquitously expressed serine/threonine kinase involved in cell contraction and F-actin turnover, which is highly amplified in human breast cancer and part of a gene expression signature for bad prognosis. Nothing is known about the in vivo function of MRCKα. To explore MRCKα function in development and in breast cancer, we generated mice lacking a functional MRCKα gene. Mice were born close to the Mendelian ratio and showed no obvious phenotype including a normal mammary gland formation. Assessing breast cancer development using the transgenic MMTV-PyMT mouse model, loss of MRCKα did not affect tumor onset, tumor growth and metastasis formation. Deleting MRCKα and its related family member MRCKβ in two triple-negative breast cancer cell lines resulted in reduced invasion of MDA-MB-231 cells, but did not affect migration of 4T1 cells. Further genomic analysis of human breast cancers revealed that MRCKα is frequently co-amplified with the oncogenes ARID4B and AKT3 which might contribute to the prognostic value of MRCKα expression. Collectively, these data suggest that MRCKα might be a prognostic marker for breast cancer, but probably of limited functional importance.

Analysis of the aromatase cytochrome P450 gene in human breast cancers

1994 ◽  
Vol 13 (3) ◽  
pp. 331-337 ◽  
Author(s):  
P Sourdaine ◽  
M G Parker ◽  
J Telford ◽  
W R Miller
Keyword(s):  
Cytochrome P450 ◽  
Breast Cancers ◽  
Human Breast ◽  
Cytochrome P450 Gene ◽  
P450 Gene
Sign in / Sign up

Export Citation Format

Share Document